Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseaseActive Not Recruiting
NCT06557772Phase 2Updated Aug 31, 2026
Sponsor: Sanofi
Coeliac Disease · Celiac Disease
United States, Argentina, Australia, Belgium, Brazil +16 more
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPDCompleted
NCT05326412Phase 2Updated Aug 31, 2026
Sponsor: Sanofi
Chronic Obstructive Pulmonary Disease
United States, Belgium, Brazil, Denmark, Germany +2 more
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic LeukemiaRecruiting
NCT06648889Phase 2Updated Aug 28, 2026
Sponsor: Goethe University
T-ALL
Germany
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as ToddlersActive Not Recruiting
NCT04936685Phase 3Updated Aug 28, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
Finland, Germany, Hungary, Spain
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorActive Not Recruiting
NCT06241118Phase 3Updated Aug 27, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +18 more
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsActive Not Recruiting
NCT05492578Phase 2, Phase 3Updated Aug 27, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Bulgaria +24 more
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Recruiting
NCT06290141Phase 3Updated Aug 26, 2026
Sponsor: Sanofi
Chronic Inflammatory Demyelinating Polyneuropathy
United States, Argentina, Belgium, Brazil, Canada +19 more
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Recruiting
NCT07457580N/AUpdated Aug 26, 2026
Sponsor: Sanofi
Type 1 Diabetes
Belgium, France, Germany, Italy, Spain +1 more
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular DegenerationActive Not Recruiting
NCT01736592Phase 2Updated Aug 26, 2026
Sponsor: Sanofi
Stargardt's Disease
United States, France
Long-Term Outcomes of Teplizumab in Routine Clinical CareRecruiting
NCT07360080N/AUpdated Aug 25, 2026
Sponsor: Sanofi
Type 1 Diabetes
United States, Israel, United Arab Emirates
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal PolypsCompleted
NCT06691113Phase 2Updated Aug 25, 2026
Sponsor: Sanofi
Chronic Rhinosinusitis Without Nasal Polyps
United States, Argentina, Belgium, Canada, Chile +8 more
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)Recruiting
NCT07116031Phase 2Updated Aug 24, 2026
Sponsor: Sanofi
Chronic Graft Versus Host Disease
United States, Belgium, Canada, China, France +8 more
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruiting
NCT07629960Phase 1, Phase 2Updated Aug 24, 2026
Sponsor: Blueprint Medicines Corporation
Advanced Solid Tumor · Non-Small Cell Lung Cancer · Colorectal Neoplasms · Pancreatic Ductal Adenocarcinoma
United States
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)Active Not Recruiting
NCT05156710Phase 2Updated Aug 21, 2026
Sponsor: Sanofi
Transplant Rejection
United States, Canada, France, Germany, Italy +2 more
Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.Not Yet Recruiting
NCT07779408Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Sanofi
Healthy Volunteers · Influenza
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host DiseaseRecruiting
NCT05996627Phase 2Updated Aug 21, 2026
Sponsor: Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
United States
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcneRecruiting
NCT06316297Phase 1, Phase 2Updated Aug 21, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Acne
United States, Australia, Canada, Puerto Rico
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaRecruiting
NCT07086976Phase 3Updated Aug 21, 2026
Sponsor: Sanofi
Autoimmune Haemolytic Anaemia
United States, Argentina, Austria, Brazil, China +12 more
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisRecruiting
NCT07112378Phase 3Updated Aug 20, 2026
Sponsor: Regeneron Pharmaceuticals
Eosinophilic Esophagitis (EoE)
United States
Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07170917Phase 2Updated Aug 20, 2026
Sponsor: Sanofi
Hidradenitis Suppurativa
United States, Australia, Canada, Chile, China +14 more
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung CancerRecruiting
NCT07133425Phase 2Updated Aug 20, 2026
Sponsor: M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer · ICI-refractory
United States
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07184996Phase 3Updated Aug 20, 2026
Sponsor: Sanofi
Ulcerative Colitis
United States, Bulgaria, Canada, China, Czechia +15 more
Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)Recruiting
NCT07038473NAUpdated Aug 19, 2026
Sponsor: Sanofi
Type 1 Diabetes
Kuwait, Saudi Arabia, United Arab Emirates
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT07185009Phase 3Updated Aug 18, 2026
Sponsor: Sanofi
Ulcerative Colitis
United States, Canada, Georgia, Japan, Lithuania +3 more
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseNot Yet Recruiting
NCT07771439Phase 3Updated Aug 18, 2026
Sponsor: Sanofi
Chronic Graft Versus Host Disease

Previous page Next page